Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The valuation ratios exhibit significant volatility over the observed period, characterized by extreme fluctuations in profit-based multiples contrasted with relatively stable revenue-based metrics. A pronounced period of instability is evident during 2023 and early 2026, suggesting substantial shifts in earnings and operating profits relative to the share price.
- Price to Earnings (P/E) and Price to Operating Profit (P/OP)
- Both ratios follow a nearly identical trajectory, marked by extreme spikes in 2023. The P/E ratio rose from a stable range of 13.36 to 19.21 in 2022 to a peak of 893.99 by December 31, 2023, while the P/OP ratio reached 138.56 in the same period. These anomalies suggest a severe temporary compression of net income and operating profit. Following a correction in 2024 and a period of valuation lows in 2025 (with P/E dipping to 11.00), a renewed upward trend is observed in 2026, with the P/E ratio climbing to 99.98 by June 30, 2026.
- Price to Sales (P/S)
- The P/S ratio demonstrates the highest level of stability among the analyzed metrics. It maintained a range between 3.17 and 5.43 throughout the period. A peak was observed in December 2023 at 5.43, followed by a gradual decline to a low of 3.17 in June 2025. The ratio recovered toward the end of the period, reaching 4.77 by June 30, 2026, indicating that the market's valuation of the company's revenue stream remained consistent despite the volatility in profitability.
- Price to Book Value (P/BV)
- The P/BV ratio shows a cyclical pattern of expansion and contraction. From a baseline of approximately 5.44 in early 2022, the ratio trended upward to a peak of 8.68 in December 2023. This was followed by a sustained decline through 2024 and 2025, reaching a nadir of 4.04 in September 2025. A sharp recovery occurred in 2026, with the ratio ascending to 7.57 by June 30, 2026, reflecting changes in the relationship between market capitalization and the company's equity base.
Overall, the divergence between the stability of the P/S ratio and the extreme variance in the P/E and P/OP ratios indicates that the valuation volatility was driven by fluctuations in profitability rather than shifts in top-line revenue or overall market capitalization. The recurring spikes in 2023 and 2026 suggest periodic intervals of significantly reduced earnings power.
Price to Earnings (P/E)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||
| Net income (loss) attributable to Merck & Co., Inc. (in millions) | ||||||||||||||||||||||||
| Earnings per share (EPS)2 | ||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||
| P/E ratio4 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| P/E Ratio, Competitors5 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
EPS
= (Net income (loss) attributable to Merck & Co., Inc.Q2 2026
+ Net income (loss) attributable to Merck & Co., Inc.Q1 2026
+ Net income (loss) attributable to Merck & Co., Inc.Q4 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q3 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.
4 Q2 2026 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
The valuation metrics exhibit significant volatility over the analyzed period, characterized by extreme fluctuations in the price-to-earnings (P/E) ratio driven primarily by instability in earnings per share (EPS) rather than consistent shifts in market share price.
- P/E Ratio Trends and Anomalies
- The P/E ratio remained relatively stable between 13.36 and 22.92 from March 2022 through March 2023. However, a period of extreme valuation expansion occurred between June 2023 and March 2024, peaking at an outlier of 893.99 in December 2023. Following this peak, the ratio normalized significantly, fluctuating between 11.00 and 20.98 from June 2024 through September 2025. A secondary surge in the P/E ratio is observed in the first half of 2026, climbing from 31.27 in March to 99.98 by June 2026.
- Earnings Per Share (EPS) Impact
- The spikes in the P/E ratio correlate directly with precipitous declines in quarterly EPS. The peak P/E ratio in December 2023 was the result of EPS dropping to a period low of 0.14. A similar pattern is evident in the 2026 data, where the P/E ratio rose to 99.98 as EPS fell from 7.38 in December 2025 to 1.29 in June 2026. Conversely, the normalization of the P/E ratio in late 2024 and 2025 coincided with a recovery and stabilization of EPS, which maintained a range between 4.80 and 7.67 during that interval.
- Share Price Correlation
- The share price demonstrated a general upward trajectory from March 2022 (88.01) to December 2023 (128.84), followed by a corrective phase reaching a low of 80.79 in June 2025. Despite these price movements, the P/E ratio's volatility was more closely tied to earnings contractions than to price appreciation. For instance, during the period of normalized P/E ratios in 2025, the share price remained relatively flat, suggesting that the market valuation reached a temporary equilibrium relative to the stabilized earnings output.
Overall, the analysis indicates that the valuation ratios were heavily distorted by periodic earnings troughs. The recurring pattern of sharp P/E increases during EPS declines suggests that the share price does not adjust downward as rapidly as earnings fall, leading to temporary but extreme valuation multiples.
Price to Operating Profit (P/OP)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||
| Operating income (loss) (in millions) | ||||||||||||||||||||||||
| Operating profit per share2 | ||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||
| P/OP ratio4 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
Operating profit per share
= (Operating income (loss)Q2 2026
+ Operating income (loss)Q1 2026
+ Operating income (loss)Q4 2025
+ Operating income (loss)Q3 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.
4 Q2 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
The valuation of the common stock relative to operating profit exhibits significant volatility over the analyzed period, characterized by cycles of extreme ratio expansion followed by periods of compression. The Price to Operating Profit (P/OP) ratio demonstrates a high sensitivity to fluctuations in operating profit per share, often moving inversely to profitability metrics.
- Share Price Trends
- The share price followed a general upward trajectory from March 2022 through December 2023, peaking at 128.84 US$. A subsequent correction occurred throughout 2024 and the first half of 2025, reaching a low of 80.79 US$ in June 2025. A recovery phase is observed toward the end of 2025 and into 2026, with prices returning to the 120-128 US$ range.
- Operating Profit per Share Dynamics
- Operating profit per share displays substantial instability. After a period of relative strength in 2022, a sharp contraction occurred in 2023, with a nadir of 0.93 US$ in December 2023. Profitability recovered strongly through 2024 and 2025, peaking at 8.73 US$ in September 2025. However, a secondary decline is evident in the first half of 2026, falling to 2.59 US$ by June 2026.
- P/OP Ratio Analysis
- The P/OP ratio remained relatively stable between 11.72 and 18.53 from March 2022 to March 2023. A period of extreme divergence followed, peaking at 138.56 in December 2023; this spike was primarily driven by the collapse in operating profit per share while the share price remained elevated. A significant compression phase occurred between June 2024 and September 2025, where the ratio dropped to a period low of 9.67 as operating profits strengthened and share prices stabilized. The ratio shifted upward again in 2026, reaching 49.74 by June 2026, reflecting a renewed misalignment between market valuation and operating performance.
Price to Sales (P/S)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||
| Sales (in millions) | ||||||||||||||||||||||||
| Sales per share2 | ||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||
| P/S ratio4 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| P/S Ratio, Competitors5 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
Sales per share
= (SalesQ2 2026
+ SalesQ1 2026
+ SalesQ4 2025
+ SalesQ3 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.
4 Q2 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
An analysis of the valuation metrics reveals a divergence between consistent operational growth and volatile market pricing. While revenue efficiency improved steadily, the market valuation multiple experienced significant fluctuations.
- Sales per Share Growth
- A consistent and linear upward trend is observed in sales per share, which rose from 21.35 USD in March 2022 to 26.98 USD by June 2026. This growth remained uninterrupted throughout the period, indicating a steady increase in the company's ability to generate revenue per share.
- Share Price Fluctuations
- The share price exhibited substantial volatility. After an initial climb to a peak of 128.84 USD in December 2023, the price entered a period of decline, reaching a trough of 80.79 USD in June 2025. A subsequent recovery phase is noted, with the price returning to 128.58 USD by June 2026.
- Price-to-Sales (P/S) Ratio Dynamics
- The P/S ratio followed the volatility of the share price rather than the steady trajectory of sales. The ratio increased from 4.12 in March 2022 to a peak of 5.43 in December 2023, suggesting a period of valuation expansion. A subsequent contraction occurred, with the ratio falling to a low of 3.17 in June 2025, coinciding with the decline in share price despite rising sales. The ratio then recovered, ending the period at 4.77 in June 2026.
The data indicates that the P/S ratio was driven primarily by shifts in market sentiment and share price volatility rather than fundamental changes in sales performance. The contraction of the multiple between December 2023 and June 2025 suggests a period where the market assigned lower value to each dollar of sales, followed by a return to higher valuation multiples in 2026.
Price to Book Value (P/BV)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||||||||||||||||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||
| Total Merck & Co., Inc. stockholders’ equity (in millions) | ||||||||||||||||||||||||
| Book value per share (BVPS)2 | ||||||||||||||||||||||||
| Share price1, 3 | ||||||||||||||||||||||||
| Valuation Ratio | ||||||||||||||||||||||||
| P/BV ratio4 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q2 2026 Calculation
BVPS = Total Merck & Co., Inc. stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.
4 Q2 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
An analysis of the valuation metrics reveals a cyclical pattern in the Price to Book Value (P/BV) ratio, characterized by significant fluctuations driven by the divergence between market pricing and equity book value over the period from March 2022 to June 2026.
- P/BV Ratio Trends
- The P/BV ratio exhibited a steady upward trajectory throughout 2022 and the first three quarters of 2023, reaching a peak of 8.68 by December 31, 2023. This was followed by a sustained contraction through 2024 and the first three quarters of 2025, where the ratio hit a period low of 4.04. A sharp recovery occurred in the final quarter of 2025 and continued into the first half of 2026, with the ratio ascending to 7.57.
- Share Price Influence
- Market price volatility served as the primary catalyst for the observed P/BV fluctuations. The maximum valuation in late 2023 coincided with a share price peak of 128.84 US$. The subsequent valuation trough in September 2025 aligned with a price decline to 84.39 US$. The rebound in the ratio during 2026 is directly attributable to the share price returning to 128.58 US$, indicating a recovery in market sentiment.
- Book Value Per Share (BVPS) Dynamics
- BVPS demonstrated a general growth trend, rising from 16.17 US$ in March 2022 to a high of 21.28 US$ in December 2025, notwithstanding volatility observed during 2023. The growth in BVPS during 2024 and early 2025 acted as a denominator effect that further compressed the P/BV ratio as share prices declined. A subsequent reduction in BVPS to 17.00 US$ by June 2026 contributed to the expansion of the P/BV ratio during the final period of analysis.
- Valuation Correlation
- The data indicates an inverse relationship between BVPS and the P/BV ratio during the 2024-2025 period; as the intrinsic book value per share increased, the market multiple decreased. However, by 2026, the valuation became more sensitive to share price appreciation than to changes in book value, leading to a rapid expansion of the multiple despite a declining BVPS.